Streptococcal and *Staphylococcus aureus* prosthetic joint infections: are they really different?

Yousra Kherabi\(^1,2\)*, Valérie Zeller\(^1,2\), Younes Kerroumi\(^1,4\), Vanina Meyssonnier\(^1,2\), Beate Heym\(^1,3\), Olivier Lidove\(^2\) and Simon Marmor\(^1,4\)

**Abstract**

Background: Staphylococci and streptococci are the most frequent pathogens isolated from prosthetic joint infections (PJIs). The aim of this study was to analyze the outcome of streptococcal and methicillin-susceptible *Staphylococcus aureus* (MSSA) PJIs.

Methods: All monomicrobial streptococcal and MSSA PJIs managed in a French Referral Center (2010–2017) were sampled from the prospective PJIs cohort study. The primary outcome of interest was the cumulative reinfection-free survival at a 2-year follow-up.

Results: Two hundred and nine patients with 91 streptococcal and 132 staphylococcal infections were analyzed. Patients with streptococcal PJI were older, and infection was more frequently hematogenous. Reinfection-free survival rates at 2-years after all treatment strategies were higher for patients with streptococcal PJI (91% vs 81%; \(P = .012\)), but differed according to the strategy. After exchange arthroplasty, no outcome differences were observed (89% vs 93%; \(P = .878\)); after debridement, antibiotics and implant retention (DAIR), the reinfection-free survival rate was higher for patients with streptococcal PJI (87% vs 60%; \(P = .062\)). For patients managed with prolonged suppressive antibiotic therapy (SAT) alone, those with streptococcal PJIs had a 100% infection-free survival (100% vs 31%; \(P < .0001\)).

Conclusions: Reinfection-free survival after DAIR and SAT was better for patients with streptococcal than those with MSSA PJIs. No difference was observed after prosthetic exchange.

Keywords: Prosthetic joint infection, Methicillin-susceptible *Staphylococcus aureus*, *Streptococcus* spp

**Background**

Although rare, prosthetic joint infection (PJI) is a severe complication of total hip and knee arthroplasties, with high morbidity and medical costs [1–4]. Staphylococci are the main pathogens isolated from PJIs, with *Staphylococcus aureus* being the most frequent species, responsible for 19–29% of PJIs, and streptococci, being the second most frequent microorganism with Gram negative bacilli, found in 9–16% of PJIs [5–7]. *Streptococcus spp.* are the most frequent microorganism isolated in hematogenous acquired PJIs [5–7].

It is now well-known that *S. aureus* virulence factors provide enhanced adherence capacity to implants [8]. Once infection is established, *S. aureus* is able to form biofilm, modify its metabolism, grow in small colonies and survive in this microenvironment [9, 10]. Streptococci can also form biofilm [11, 12], but less is known about it than that of *S. aureus* [13]. Biofilm active
antibiotics are not recommended to treat streptococcal infections [1, 14], but the use of rifampicin-combination therapy is not rare and remains controversial [15, 16]. Streptococci usually have very low minimum inhibitory concentration (MIC). Indeed, amoxicillin MIC distribution ranges for \( S. agalactiae \) are 0.016–0.125 mg/L, i.e. much lower than \( S. aureus \) (oxacillin MIC distribution for methicillin-susceptible \( S. aureus \) 0.06–2 mg/L) [17]. Clinical experience suggests that streptococcal PJI outcomes are better than those with \( S. aureus \) [13, 18].

Numerous studies on \( S. aureus \) PJI treated with debridement, antibiotics and implant retention (DAIR) have been published over the last decade [19–21]. Only a few large retrospective studies addressed streptococcal PJIs [15, 16, 22, 23]. Their characteristics and outcomes remain less known. Lora-Tamayo et al. published the largest study including 462 DAIR-treated PJIs [15]. Their outcomes did not appear to be better than those of patients with \( S. aureus \) PJIs, as 42% of the patients experienced failure. Another multicentric study including 70 streptococcal PJIs found that DAIR and \( S. agalactiae \) were associated with a higher risk of failure [16]. At 2-year follow-up, 51% of patients treated with DAIR had relapsed. However, the authors of two small comparative studies on DAIR-treated patients concluded that streptococcal PJI outcomes were better than those of \( S. aureus \) PJIs [24, 25]. A large study on patients treated with DAIR for late acute PJI also indicated better results for streptococcal than MSSA infections (respective failure rates 37% vs 55%) [26]. For acute hematogenous PJIs, \( S. aureus \) was identified as a negative prognostic factor compared to other etiologies [18].

The lack of studies analyzing specifically streptococcal and \( S. aureus \) PJI outcomes and treatments, and the high rates of treatment failure reported for streptococcal PJIs treated with DAIR [15, 16], led us to question outcomes between the two microorganisms and according to the therapeutic strategy applied.

We performed an observational cohort study analyzing the outcomes of streptococcal and methicillin-susceptible \( S. aureus \) (MSSA) PJIs, their epidemiological and clinical characteristics, and their therapeutic strategies.

### Patients and methods

#### Study design

This cohort study was conducted in a French National Referral Center for Bone-and-Joint Infections (BJI) [27]. All patients admitted to our Referral Center for PJIs are registered in the prospective PJI cohort (NCT 01963520, NCT 02801253). Epidemiological, clinical, microbiological, therapeutic (surgery and antibiotic therapy), adverse event and outcome data of each patient are entered prospectively. The primary outcome of the cohort is the 2-year-reinfection-free survival.

All patients, 18 years of age or older, treated from January 2010 to July 2017 for a streptococcal (any species) or MSSA hip and/or knee PJI(s), with a curative strategy or prolonged suppressive antibiotic therapy (SAT), were included. Polymicrobial, meticillin-resistant \( S. aureus \) (MRSA) and enterococcal PJIs were not included.

A retrospective analysis of those prospectively collected data was performed.

#### PJI definitions and classification

PJI was defined as the isolation of the same microorganism from ≥2 cultures of preoperative joint-fluid and/or intraoperative tissue specimens plus at least 1 of the following criteria: a sinus tract communicating with the prosthesis, local inflammatory signs, C-reactive protein >5 mg/L and/or radiological findings (i.e., periosteal bone formation, subchondral osteolysis) [28].

PJIs lasting for < 3 weeks were defined as acute, and the others as chronic [1, 6]. Early-postoperative infection was defined as surgical site pain, redness with or without drainage, associated or not with fever, occurring within 30 days after joint arthroplasty. Late-chronic infection was defined as progressive pain, joint dysfunction with or without a fistula, occurring more than 30 days after joint arthroplasty. A hematogenous infection was defined as occurring after a symptom-free interval of at least 30–days post-surgery, with sudden onset of pain, joint dysfunction with or without fever, and/or chills [7].

#### Microbiological diagnosis

Preoperative joint aspiration was performed for all patients, except for patients with an early postoperative PJI operated right away after admission. Joint aspiration was done in the department of radiology under strict sterile conditions [7]. During surgery at least 3 intraoperative samples of bone and/or synovium that appeared inflamed were collected before starting antibiotics. Tissue or bone specimens were disrupted by vigorous crushing in sterile mortars with sterile diluents. For cultures, aliquots of the resulting suspensions and/or synovial fluid were inoculated onto PolyViteX (PVX) chocolate agar (incubated under 5% CO\(_2\)) and anaerobic Columbia agar plates (bioMérieux, Marcy-l’Etoile, France) and into aerobic (Hemoline, bioMérieux), and into anaerobic enrichment broths (Schaedler broth, bioMérieux). Cultures were incubated for 10 days for aerobic and 14 days for anaerobic cultures. On day 10 or 14, or earlier if bacterial growth was visible, broths were subcultured on PVX chocolate agar and anaerobic Columbia agar plates, and incubated at 37 °C for 48 h [7].
Bacteria were identified to species with the rapid ID 32A kit (bioMérieux) and, since January 2012, by mass spectrometry (MALDI biotyper, Bruker Dalton, Bremen, Germany). Antibiotic-susceptibility testing used the standard disk-diffusion method, according to the recommendations of the French Society of Microbiology [29]. Molecular biology methods (Polymerase Chain Reaction) were not used to identify microorganism.

Therapeutic strategies

Curative surgical treatment included DAIR for early postoperative infections (developing within 30 days postsurgery) and acute hematogenous PJIs lasting <2 weeks without prosthesis loosening. Otherwise, complete prosthesis exchange arthroplasty was done, most often one-stage exchange [30]. Two-stage exchange was performed if several negative prognostic factors were associated (irradiated bone, severe immunosuppression, large bone graft required ...) (Fig. 1). Five MSSA-PJI patients underwent definitive prosthesis removal.

Antibiotic therapy for acute PJI treated with DAIR lasted 6 weeks: 2–4 weeks intravenous, followed by a 2–4-week oral regimen. For chronic PJIs treated with prosthesis exchange, 12-week antibiotic therapy comprised 2–4 weeks of intravenous therapy. It was shortened to 6 weeks in January 2017.

Pathogen-specific antibiotic therapies were based on international and French recommendations [1, 31] and our local procedures, detailed in a recent article [32]. First choice treatment for streptococcal infection in non-allergic patients was amoxicillin, given IV at high doses and prolonged infusion. Amoxicillin was also used in these patients for the oral switch, 2–3 g, thrice daily. Before January 2013, rifampicin was used to treat streptococcal and staphylococcal PJIs. Since then, rifampicin in combination has only been prescribed for staphylococcal PJIs [32].

For MSSA PJI, continuous IV cefazolin infusion combined to IV rifampicin (600–900 mg, twice a day) was the first choice treatment followed by oral therapy with levofloxacin (750 mg/day to 500 mg twice a day) and rifampicin (600–900 mg, twice a day) [32, 33].

SAT was not prescribed for patients who underwent curative surgical treatment (DAIR, prosthesis exchange or definitive prosthesis removal). This specific treatment option was applied right away to patients at high surgical risk, recurrent PJIs (>2 PJIs), or who refused surgery (Fig. 1). Initial antibiotic therapy was administered intravenous for 7–10 days and then continued orally. SAT was given for at least 3 months and up to several years, depending on patient’s evolution and antibiotic tolerance. Drug dosage for oral SAT was 1 g thrice a day for amoxicillin, cloxacillin and cephalexin, and 600 mg thrice a day for clindamycin. SAT was discontinued when a serious adverse event occurred as defined by the Food and Drug Administration [34].

All treatment options were discussed in multidisciplinary meetings, requiring the presence of at least an orthopedic surgeon, a microbiologist and an infectious disease specialist.

Outcome measures

Patients were followed for at least 2 years. The following events were recorded: reinfection, either relapse with the same pathogen or new infection with a different microorganism, and death from any cause. No patient was lost-to-follow-up at 2 years.

Statistical analyses

The primary outcome of interest was the cumulative reinfection-free survival at a 2-year follow-up. Qualitative variables were expressed as number (%) and compared using χ² test. Quantitative variables were first assessed for normality, expressed as median [interquartile range (IQR)], and then compared with the non-parametric Mann–Whitney U-test. The reinfection-free–survival rate was analyzed using the Kaplan–Meier method and expressed as the mean ± standard deviation. The Mantel–Cox log-rank test was used to calculate survival-distribution difference. A P value < 0.05 was considered significant. All statistical tests were computed with SPSS.20 software.

Fig. 1 Surgical and medical strategies for prosthetic joint infections (PJIs) treatment. PJIs prosthetic joint infections, DAIR debridement, antibiotics and implant retention, SAT prolonged suppressive antibiotic therapy
Ethics approval
Written informed consent was obtained from all patients and the cohort was approved by the Ethics Committee of Île-de-France (N° PP 14–034).

Results
Patient and PJI characteristics
During the 7.5-year study period, 988 PJIs in 918 patients were managed in our center. Two hundred and nine patients, 86 with 91 streptococcal and 123 with 132 MSSA PJIs, for a total of 223 PJIs, were included (Fig. 2). Five patients with streptococcal and 9 with MSSA PJIs had multiple concomitant prosthetic hip or knee infections.

Patients’ description and PJIs characteristics are reported in Table 1.

Patients with streptococcal PJI were significantly older than those with MSSA PJI, had cancer more frequently within the last 5 years and their PJIs were often hematogenously acquired (88% vs 46%; \( P < 0.0001 \)). Patients with MSSA experienced more prior PJI treatment failures in another center (40% vs 16%; \( P < 0.0001 \)).

Microbiology
Streptococcal species isolated from these 86 patients’ PJIs are detailed in Additional file 1: Table S1. The most frequently isolated species was *Streptococcus agalactiae* (33%), *Streptococcus dysgalactiae* (20%) and *Streptococcus mitis/oralis* (16%).

Surgical and medical treatments
Details on treatment strategies and antibiotic therapy are given in Table 2. Rates of curative surgical strategies, ie, exchange arthroplasty and DAIR, did not differ between patients with streptococcal and those with MSSA PJIs.

One-stage exchange arthroplasty was by far the most frequent operation. Among these 124 patients, prior treatment failure was significantly more frequent in patients with MSSA PJIs (35/74; 47% vs 9/50; 18%, \( P < 0.0001 \)). Furthermore, 8 patients with streptococcal and 9 with MSSA acute PJIs of a loosened prosthesis or hematogenous infection lasting >2 weeks underwent exchange arthroplasty: 16 underwent one-stage and one MSSA PJI-patient underwent two-stage exchange arthroplasty. All but 2, received preoperative antibiotic therapy for a median of 7 [2–18] days before exchange arthroplasty.

Six patients with prosthetic hip infection underwent two-stage arthroplasty. No antibiotic-loaded cement was used.

Moreover, 5 patients with MSSA PJIs had their prostheses definitively removed (2 hip-resection arthroplasties and 3 knee arthrodeses).

SAT was prescribed significantly more often to treat streptococcal PJI patients (24% vs 8%, \( P = 0.001 \)). None of the SAT-patients underwent surgery for their ongoing PJI. All streptococcal PJI-patients received first-line antibiotic therapy with amoxicillin, intravenously and then orally, except for 5 patients who had oral amoxicillin right away. All SAT-patients with MSSA PJIs received intravenous cefazolin or oxacillin, followed by oral cloxacillin \( (n = 8) \), clindamycin \( (n = 2) \) or cefalexin \( (n = 2) \).

Outcomes
At 2 years (Table 3), all therapeutic strategies combined, reinfection-free survival was higher for patients with streptococcal than MSSA PJIs (Fig. 3A). Eight patients
with streptococcal PJIs experienced reinfections (5 relapses, 3 new-pathogen PJIs) compared to 26 patients with MSSA PJIs (15 relapses, 11 new-pathogen PJIs).

Between patients with streptococcal and those with MSSA PJIs, differences were observed according to the medical–surgical strategy. After exchange arthroplasty, no difference in outcome was noted and reinfection-free survival was ~ 90% for streptococcal and MSSA PJI-patients (Fig. 3B). Streptococcus dysgalactiae was responsible for both streptococcal knee-arthroplasty relapses. The 2 patients with MSSA PJIs who relapsed were 78-year-old males. New infections occurred in 3 patients with streptococcal PJIs and 6 with MSSA PJIs.

However, after DAIR, reinfection-free survival was higher for patients with streptococcal PJIs (Fig. 3C). Three relapses (21%) occurred with S. agalactiae, S. dysgalactiae or S. salivarius, without any new-pathogen infections. Patients with MSSA PJIs experienced 8 relapses (28%) and 5 new infections.

For patients with streptococcal PJIs treated with prosthesis exchange or DAIR, no outcome differences were observed between those who were on rifampicin or not (Fig. 3D).

Table 1  Baseline characteristics of patients with Streptococcal or MSSA PJIs

| Characteristic                          | Streptococcal PJIs patients (n = 86) | MSSA PJIs patients (n = 123) | P     |
|----------------------------------------|------------------------------------|----------------------------|-------|
| Age (years)                            | 76 [68–84]                         | 73 [65–80]                 | 0.030 |
| Sex (male/female)                      | 41 (48) / 45 (52)                  | 63 (51) / 60 (49)          | 0.674 |
| ASA score ≥ 3                          | 41 (48)                            | 64 (52)                    | 0.575 |
| Body mass index (kg/m.²)               | 28 [24–30]                         | 27 [23–30]                 | 0.318 |
| Atrial fibrillation                    | 7 (20)                             | 19 (15)                    | 0.457 |
| Cardiovascular diseases                | 34 (40)                            | 34 (28)                    | 0.072 |
| Hypertension                           | 57 (66)                            | 76 (62)                    | 0.466 |
| Immunosuppressive therapy              | 2 (2)                              | 7 (6)                      | 0.315 |
| Rheumatological inflammatory diseases  | 4 (5)                              | 6 (5)                      | 1.000 |
| Diabetes                               | 10 (11)                            | 25 (20)                    | 0.132 |
| Chronic dermatosis                     | 8 (9)                              | 6 (5)                      | 0.262 |
| Malignancy within the last 5 years     | 8 (9)                              | 3 (2)                      | 0.054 |
| Renal insufficiency.a                   | 4 (5)                              | 6 (5)                      | 1.000 |
| Cirrhosis                              | 1 (1)                              | 3 (2)                      | 0.646 |
| Prosthetic knee infection              | 31 (36)                            | 55 (45)                    | 0.253 |
| Prosthetic hip infection               | 55 (64)                            | 68 (55)                    | 0.253 |
| Multiple concomitant PJs               | 5 (6)                              | 7 (6)                      | 1.000 |
| Bilateral knee PJs                     | 2 (2)                              | 4 (3)                      | 1.000 |
| Bilateral hip PJs                      | 3 (3)                              | 3 (2)                      | 1.000 |
| Prior PJI-treatment and failure         | 14 (16)                            | 49 (40)                    | <0.0001 |
| Acute PJs (lasting < 3 weeks at admission) | 42 (49)                          | 45 (37)                    | 0.088 |
| PJI duration before surgery in our Center (days) | 6 [2–12]                        | 7 [4–13]                   | 0.356 |
| Postoperative PJI                      | 0                                  | 17 (38)                    | <0.0001|
| Hematogenous PJI                       | 42 (100)                           | 24 (53)                    | <0.0001|
| Unknown                                | 0                                  | 4 (9)                      | 0.117 |
| Chronic PJs (lasting > 3 weeks at admission) | 44 (51)                         | 78 (63)                    | 0.088 |
| PJI duration before surgery in our Center (days) | 200 [97–355]                    | 171 [113–330]              | 0.695 |
| Postoperative PJs                      | 2 (5)                              | 30 (38)                    | 0.001 |
| Hematogenous PJs                       | 33 (75)                            | 34 (44)                    | 0.001 |
| Unknown                                | 9 (20)                             | 14 (18)                    | 0.811 |

ASA American Society of Anesthesiologists, DAIR debridement, antibiotics and implant retention, MSSA meticillin-susceptible Staphylococcus aureus, PJI prosthetic joint infection

a Results are expressed as number (%) or median [interquartile range] for continuous variables

b eGFR < 30 mL/min/1.73 m²
Table 2  Treatment strategies for patients with Streptococcal or MSSA PJIs

| Treatment strategy                        | Streptococcal PJIs (n = 86) | MSSA PJIs (n = 123) | P    |
|------------------------------------------|-----------------------------|---------------------|------|
| Exchange arthroplasty                    | 51 (59) ^a                  | 79 (64)             | 0.389|
| Time (days) to prosthesis exchange       | 22 [5–196]                  | 92 [12–257]         | 0.062|
| One-stage exchange                       | 50 (98)                     | 74 (94)             | 0.670|
| Two-stage exchange                       | 1 (2)                       | 5 (6)               | 0.404|
| DAIR                                     | 14 (16)                     | 29 (24)             | 0.306|
| Time to DAIR (days)                      | 5 [2–9]                     | 8 [4–12]            | 0.042|
| Mobile device exchange                   | 8 (57)                      | 14 (48)             | 0.51 |
| Definitive prosthesis removal            | 0                           | 5                   | 0.079|
| Antibiotics combined with surgery        |                             |                     |      |
| Treatment duration (days)                | 87 [85–92]                  | 87 [64–92]          | 0.444|
| IV duration (days)                       | 32 [29–36]                  | 33 [29–44]          | 0.265|
| Beta-lactams > 14 days                   | 65 (76)                     | 85 (69)             | <0.0001|
| Rifampicin > 14 days                     | 29 (35)                     | 88 (73)             | <0.0001|
| Prolonged suppressive antibiotic therapy | 21 (24)                     | 10 (8)              | 0.001|
| Initial IV antibiotics                   | 16 (55)                     | 8 (80)              | 1.000|
| IV duration (days)                       | 9 [4–23]                    | 16 [11–27]          | 0.071|
| Duration (days)                          | 405 [375–741]               | 366 [136–640]       | 0.016|

* Results are expressed as number (%) or median (interquartile range) for continuous variables

DAIR: Debridement, antibiotics and implant retention, IV: Intravenous, MSSA: Methicillin-susceptible Staphylococcus aureus, PJIs: Prosthetic joint infections

Table 3  Reinfection-free survival rates for patients with Streptococcal or MSSA PJIs after 2 years of follow-up according to treatment

| Treatment     | Streptococcal PJIs | Staphylococcal PJIs | P (Log-rank Mantel–Cox) |
|---------------|--------------------|---------------------|-------------------------|
| All strategies| 91.4 ± 0.03 ^a     | 81 ± 0.03           | 0.012                   |
| Prosthesis exchange | 89.4 ± 0.04 | 92.7 ± 0.03         | 0.878                   |
| DAIR          | 86.7 ± 0.08        | 60 ± 0.09           | 0.062                   |
| SAT           | 100                | 31.1 ± 0.17         | <0.0001                 |

* Results are expressed as mean percentage ± standard deviation

Discussion
The results of our large observational cohort study on outcomes and characteristics of streptococcal and MSSA PJIs showed that patients with streptococcal PJIs were older, more frequently had cancer, and their hematogenous infection rate was higher. These findings are consistent with previous observations [15, 22]. Prior PJI-treatment failure before admission to our center was significantly more frequent for patients with MSSA than streptococcal PJIs.

Our analysis showed also that streptococcal PJIs had better outcomes than MSSA for all therapeutic strategies combined, with differences observed according to the medical–surgical strategy. Notably, no difference was observed among patients treated with SAT, those with streptococcal PJIs (Fig. 3D) had better outcomes, and none had treatment failures. Only 1 patient stopped amoxicillin after 10 months, because of Clostridiodes difficile colitis; he died 9 months later of metastatic prostate neoplasia. Five (42%) patients with MSSA PJIs relapsed: 1 following treatment discontinuation after 1 year of cloxacillin relayed by cephalexin and four others while taking oral cloxacillin.

Mains results are summarized in an overview figure (Fig. 4).

S. aureus was previously identified as a risk factor for DAIR failure [26, 35, 36]. Its notable biofilm-formation capacity, a very efficient tool for bacterial survival, its longer interval before DAIR, and lower antibiotic susceptibility can explain the higher treatment-failure rate [17].
**Fig. 3** Cumulative reinfection-free survival rates of patients with streptococcal or methicillin-susceptible S. aureus prosthetic joint infection (PJIs).

**A** Entire population, all strategies (n = 209; 86 streptococcal and 123 MSSA patients). **B** After prosthesis exchange (n = 130; 51 streptococcal and 79 MSSA patients). **C** After debridement and implant retention (DAIR) (n = 43; 14 streptococcal and 29 MSSA patients). **D** After prolonged suppressive antibiotic therapy (SAT) (n = 31; 21 streptococcal and 10 MSSA patients).

**Fig. 4** Research summary. JIs joint infections, PJI prosthetic joint infection, MSSA methicillin-susceptible *Staphylococcus aureus*, DAIR debridement, antibiotics and implant retention, SAT prolonged suppressive antibiotic therapy.
As Wouthuyzen-Bakker et al. [26] emphasized, an unrecognized, chronic PJI with a sudden clinical onset could be an additional reason for treatment failure in some patients. More than one-quarter of our patients with MSSA PJIs treated with DAIR relapsed, but re-infection was also attributed to new-pathogen PJIs, not observed in the streptococcal group. Since the numbers of patients treated with DAIR either for streptococcal or MSSA PJIs were small, conclusions should be drawn cautiously. Indeed, to date, DAIR remains, in our center, the treatment of choice for acute MSSA PJIs evolving for less than 2 weeks and without prosthesis loosening. Nevertheless, these results suggest a difference in populations and PJI types between these pathogens, with the MSSA PJI patients having a higher risk of re-infection. To improve patient care, the cohort patients that benefit from DAIR needs to be further characterized.

These crucial points of the pathophysiology of foreign-body infection could also explain the good and similar outcomes of our patients with streptococcal or MSSA PJIs treated with prosthesis exchange. The strength and originality of our study was to include many patients treated with exchange arthroplasty, especially one-stage exchanges, which had not been addressed previously. Exchange arthroplasty removes the entire foreign body containing the bacteria embedded in biofilm. In our experience, one-stage exchange arthroplasty has a very low relapse rate (≤ 5%) in chronic prosthetic hip infections [30], even MSSA PJIs, as shown herein. Interestingly, more MSSA-patients had underwent prior PJI management before admission to our center (40% vs 16%), but their outcome was not different from streptococcal PJI patients, and the number of relapses was very low (2.5%). One-stage arthroplasty is a valid and advantageous option for chronic PJIs. In their multicenter study on 70 streptococcal PJIs, Mahieu et al. also obtained good results with one- and two-stage arthroplasty, without any relapses [16]. However, the question remains whether one-stage exchange arthroplasty should be used as first-line treatment for acute hematogenous infection of a loosened prosthesis or subacute PJIs lasting > 2 weeks with a high bacterial load. In those settings, outcomes after exchange arthroplasty may be less favorable than for chronic PJIs [37, 38] and can lead to septic shock. The rationale behind why we start antibiotics preoperatively is to reduce the bacterial load and local inflammation. However, our findings have to be confirmed by future studies.

Another important and unresolved question is the benefit of rifampicin against streptococcal PJIs. During the first 3 years of this cohort, patients received combination therapy with rifampicin before being stopped because of the absence of data supporting its use and the occurrence of rifampicin-induced adverse events in one-third of patients (data not shown) [15, 39]. Notably, outcomes of patients with streptococcal PJI treated with or without rifampicin did not differ. Successful complete removal of the implants during exchange arthroplasty is certainly an important argument not to use rifampicin. Based on their large study, Lora-Tamayo et al. concluded that rifampicin combination therapy for streptococcal PJIs treated with DAIR could improve the outcome, but has to be confirmed in further studies [15]. However, according to Mahieu et al’s multicenter study [16], rifampicin combination therapy did not achieve better outcomes.

Finally, streptococcal PJI patients treated with SAT had better outcomes than those with MSSA infections. This therapeutic option was prescribed more frequently to streptococcal PJI patients, especially those very old and frail, or with relapsing PJIs. These patients did not undergo surgery. Amoxicillin having excellent activity against Streptococcus spp. and high bioavailability yielded very good outcomes with good tolerance. No relapses occurred and only one patient stopped amoxicillin because of Clostridioides difficile colitis. Although this strategy avoids surgery and achieves good infection control, it should be reserved for patients at high surgical risk or those with frequent, recurrent infections. On the other hand, five MSSA PJI patients relapsed, four while taking oral cloxacillin. Lower Staphylococcus aureus antibiotic susceptibility and cloxacillin bioavailability could explain the difference observed. American guidelines recommend cephalexin, dicloxacillin or clindamycin for SAT [1].

Our study has several limitations. First, it was a monocenter study conducted in a highly specialized referral center for treatment of complex BJI, thereby limiting the generalizability of our findings and carrying a risk for selection bias. For example, more MSSA PJI-patients had prior management of their PJI before admission to our center. This may have had an impact on our results. Moreover, as already mentioned in the methodology section, there were different antibiotic treatment protocols during the study period. The number of DAIR- or SAT-treated patients was small. Unlike the MSSA group, several streptococcal species were included, resulting in heterogeneity of the population.

In conclusion, we described a large cohort study analyzing streptococcal and MSSA PJIs. DAIR obtained a better re-infection-free survival rate for patients with streptococcal than MSSA PJIs, making it a valid therapeutic option for acute streptococcal PJI, if initiated very early. Outcomes after one-stage exchange arthroplasty were comparable with low relapse rates, highlighting the crucial role of this treatment strategy for chronic PJIs, even after DAIR failure. SAT is an alternative option for very old and frail patients at high surgical risk who...
develop streptococcal PJIs. The microorganism type, in this case *S. aureus* or *Streptococcus* spp., is one of several important factors guiding medico-surgical strategy decision, in addition to infection duration, underlying comorbidities, functional state and surgical procedure complexity.

**Supplementary Information**
The online version contains supplementary material available at https://doi.org/10.1186/s12879-022-07532-x.

**Additional file 1: Table S1.** Streptococcal Species Isolated from 86 Patients’ PJIs.

**Acknowledgements**
We thank Janet Jacobson for her editorial assistance.

**Author contributions**
YKh, VZ, YKe conceived the study, searched the literature, designed the study, analyzed the data, interpreted the results, and drafted the report. All authors collected the data and revised critically the report for important intellectual content. VZ, YKe, YKe and SM supervised the study, interpreted the results and revised critically the report. All authors give final approval of the version to be published.

**Funding**
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Availability of data and materials**
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**
Written informed consent to participate was obtained from all patients and the cohort was approved by the Ethics Committee of Île-de-France. All methods were carried out in accordance with the Declaration of Helsinki.

**Consent for publication**
Written informed consent for publication was obtained from all patients and the cohort was approved by the Ethics Committee of Île-de-France.

**Competing interests**
The authors declare that they have no competing interests.

**Author details**
1 Centre de Référence des Infections Ostéo-Articulaires Complexes, Groupe Hospitalier Diaconesses-Croix Saint-Simon, 125, rue d’Avron, 75020 Paris, France. 2 Service de Médecine Interne et Infectiologie, Groupe Hospitalier Diaconesses-Croix Saint-Simon, 125, rue d’Avron, 75020 Paris, France. 3 Laboratoire des Centres de Santé et Hôpitaux d’Île-de-France, Groupe Hospitalier Diaconesses-Croix Saint-Simon, 125, rue d’Avron, 75020 Paris, France. 4 Service de Chirurgie Osseuse et Traumatologique, Groupe Hospitalier Diaconesses-Croix Saint-Simon, 125, rue d’Avron, 75020 Paris, France. Received: 14 February 2022 Accepted: 10 June 2022 Published online: 17 June 2022

**References**
1. Osmon DR, Berbari EF, Berendt AR, Lew D, Zimerlini W, Steckelberg JM, et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2015;56:e1-25.
2. Tande AJ, Gomez-Ureña EO, Berbari EF, Osmon DR. Management of prosthetic joint infection. Infect Dis Clin North Am. 2017;31:237–52.
3. Kurtz SM, Lau EC, Son M-S, Chang ET, Zimerlini W, Parvizi J. Are we winning or losing the battle with periprosthetic joint infection: trends in periprosthetic joint infection and mortality risk for the medicare population. J Arthroplasty. 2018;33:3238–45.
4. Kurtz SM, Lau E, Schmier J, Ong KL, Zhao K, Parvizi J. Infection burden for hip and knee arthroplasty in the United States. J Arthroplasty. 2008;23:984–91.
5. Triffault-Fillé C, Ferry T, Laurent F, Pradat P, Dupieux C, Conrad A, et al. Microbiologic epidemiology depending on time to occurrence of prosthetic joint infection: a prospective cohort study. Clin Microbiol Infect. 2019;25:353–8.
6. Benito N, Franco M, Ribera A, Soriano A, Rodriguez-Pardo D, Sotli L, et al. Time trends in the aetiology of prosthetic joint infections: a multicentre cohort study. Clin Microbiol Infect. 2016;22(732):e1-8.
7. Zeller V, Kerroumi Y, Meyssonnier V, Heym B, Metten M-A, Desplaces N, et al. Analysis of postoperative and hematogenous prosthetic joint-infection microbiological patterns in a large cohort. J Infec. 2018;76:326–34.
8. Post V, Wahl P, Uckay I, Oschner P, Zimerlini W, Corvec S, et al. Phenotypic and genotypic characterisation of *Staphylococcus aureus* causing musculo-skeletal infections. Int J Med Microbiol. 2014;304:565–76.
9. Vaudaux P, Kelley WL, Lew DP. *Staphylococcus aureus* small colony variants: difficult to diagnose and difficult to treat. Clin Infect Dis. 2008;46:968–70.
10. Sendi P, Rohrbach M, Graber P, Frei R, Ochsner PE, Zimerlini W, Staphylococcus aureus small colony variants in prosthetic joint infection. Clin Infect Dis. 2006;43:961–7.
11. Rosini Ro, Margarit I. Biofilm formation by *Streptococcus* agalactiae: influence of environmental conditions and implicated virulence factors. Front Cell Infect Microbiol. 2015. https://doi.org/10.3389/fcimb.2015.00006.
12. Marks LR, Reddinguer RM, Hakansson AP. Biofilm formation enhances fomite survival of *Streptococcus pneumoniae* and *Streptococcus pyogenes*. Infect Immun. 2014;82:1141–6.
13. Speziale P, Geoghegan JA. Biofilm formation by *Staphylococcus* and *Streptococcus*: structural, functional, and regulatory aspects and implications for pathogenesis. Front Cell Infect Microbiol. 2015. https://doi.org/10.3389/fcimb.2015.00031.
14. Ariza J, Cobo J, Baraia-Etxaburu J, Benito N, Boni G, Cabo J et al. Executive summary of management of prosthetic joint infections. Clinical practice guidelines by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). Enferm Infect Microbiol Clin. 2017;35(3):189–95. https://doi.org/10.1016/j.eimc.2016.08.012.
15. Lota-Tamayo J, Senneville E, Ribera A, Bernard L, Dupon M, Zeller V, et al. The not-so-good prognosis of *Streptococcal* periprosthetic joint infection managed with implant retention: the results of a large multicenter study. Clin Infect Dis. 2017;64:1742–52.
16. Mahieu R, Dubèe V, Seegers V, Lemañé C, Ansart S, Bernard L, et al. The prognosis of prosthetic joint infection is still difficult to diagnose and difficult to treat. Clin Infect Dis. 2019;68:911–25.
17. MIC EUCAST. https://mic.eucast.org/search/. Accessed 29 Apr 2022.
18. Rodrigoz D, Pigrau C, Euba G, Cobo J, Garcia-Lechuz J, Palomino J, et al. Acute haematogenous prosthetic joint infection: prospective evaluation of medical and surgical management. Clin Microbiol Infect. 2010;16:1789–95.
19. Lota-Tamayo J, Murillo Q, Inbarren JA, Soriano A, Sánchez-Sarmolin Moj, Baraia-Etxaburu JM, et al. A large multicenter study of methicillin-susceptible and methicillin-resistant *Staphylococcus aureus* prosthetic joint infections managed with implant retention. Clin Infect Dis. 2013;56:182–94.
20. Lesens D, Ferri MS, Forestier E, Beteol-Nevers E, Pavese P, Piet E, et al. Should we expand the indications for the DAIR (debridement, antibiotic therapy, and implant retention) procedure for *Staphylococcus aureus* prosthetic joint infections? A multicenter retrospective study. Eur J Clin Microbiol Infect Dis. 2008;27:1949–56.
21. Lota-Tamayo J, Euba G, Cobo J, Horcajada JP, Soriano A, Sandoval E, et al. Short-versus long-duration levofloxacin plus rifampicin for acute
staphylococcal prosthetic joint infection managed with implant retention: a randomised clinical trial. Int J Antimicrob Agents. 2016;48:310–6.

22. Kernéis S, Plainvert C, Barnier J-P, Tazi A, Dmytruk N, Gislain B, et al. Clinical and microbiological features associated with group B Streptococcus bone and joint infections, France 2004–2014. Eur J Clin Microbiol Infect Dis. 2017;36:1679–84.

23. Seng P, Vernier M, Gay A, Pinelli P-O, Legré R, Stein A. Clinical features and outcome of bone and joint infections with streptococcal involvement: 5-year experience of interregional reference centres in the south of France. New Microbes New Infect. 2016;12:8–17.

24. Zürcher-Pfund L, Uçkay I, Legout L, Gamulin A, Vaudaux P, Peter R. Pathogen-driven decision for implant retention in the management of infected total knee prostheses. Int Orthop. 2013;37:1471–5.

25. Betz M, Abrassart S, Vaudaux P, Gjika E, Schindler M, Billières J, et al. Increased risk of joint failure in hip prostheses infected with Staphylococcus aureus treated with debridement, antibiotics and implant retention compared to Streptococcus. Int Orthop. 2015;39:397–401.

26. Wouthuyzen-Bakker M, Sebillotte M, Gjika E, Schindler M, Billières J, et al. Timing of implant removal for late acute periprosthetic joint infection: a multicenter observational study. J Infect. 2019;79:199–205.

27. Ferry T, Seng P, Mainard D, Jenny J-Y, Laurent F, Senneville E, et al. The CRIOAc healthcare network in France: a nationwide Health Ministry program to improve the management of bone and joint infection. Orthop Traumatol Surg Res OTSR. 2019;105:185–90.

28. Zimmerli W. Clinical presentation and treatment of orthopaedic implant-associated infection. J Intern Med. 2014;276:111–9.

29. Comité de l’Antibiogramme de la Société Française de Microbiologie (CASFM), European Committee on antimicrobial susceptibility testing of the European Society of Clinical Microbiological and Infectious Diseases (EUCAST). Recommendations 2016. URL: www.sfmmicrobiologie.org.

30. Zeller V, Lhotellier L, Marmor S, Leclerc P, Krain A, Graff W, et al. One-stage exchange arthroplasty for chronic periprosthetic hip infection: results of a large prospective cohort study. J Bone Jt Surg Am. 2014;96:e1.

31. Haute Autorité de Santé - Prothèse de hanche ou de genou : diagnostic et prise en charge de l’infection dans le mois suivant l’implantation. https://www.has-sante.fr/jcms/c_1228574/fr/prothese-de-hanche-ou-de-genou-diagnostic-et-prise-en-charge-de-l-infection-dans-le-mois-suitant-l-implantation. Accessed 20 May 2022.

32. Le Vavasseur B, Zeller V. Antibiotic therapy for prosthetic joint infections: an overview. Antibiot Basel Switz. 2022;11:486.

33. Zeller V, Durand F, Kozis M-D, Lhotellier L, Ziza J-M, Mamoudy P, et al. Continuous cefazolin infusion to treat bone and joint infections: clinical efficacy, feasibility, safety, and serum and bone concentrations. Antimicrob Agents Chemother. 2009;53:883–7.

34. Commissioner O of the. What is a Serious Adverse Event? FDA. 2020.

35. Byren I, Bejon P, Atkins BL, Angus B, McLardy-Smith P, et al. One hundred and twelve infected arthroplasties treated with “DAIR” (debridement, antibiotics and implant retention): antibiotic duration and outcome. J Antimicrob Chemother. 2009;63:1264–71.

36. Thakrar RR, Horriat S, Kayani B, Haddad FS. Indications for a single-stage exchange arthroplasty for chronic prosthetic joint infection: a systematic review. Bone Jt J. 2019;101B(1_suppl_A):19–24.

37. Fiaux E, Titecat M, Robineau O, Lora-Tamayo J, El Samad Y, Etienne M, et al. Outcome of patients with streptococcal prosthetic joint infections with special reference to rifampicin combinations. BMC Infect Dis. 2016;16:368.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.